Interleukin-2 to mediate cancer regression | Peter Attia, M.D. & Steven Rosenberg, M.D., Ph.D.

Well SupportedIn 1984, Interleukin-2 showed the first reproducible tumor regression mediated by a deliberate immunologic maneuver in a patient with melanoma.

Partially SupportedLymphocytes grown in culture with Interleukin-2 can retain their immune function both in the laboratory and in vivo.

Partially SupportedLymphokine-activated killer (LAK) cells grown in Interleukin-2 could destroy cultured cancer cells.

Partially SupportedInterleukin-2 administration was largely ineffective in treating cancer patients until a modified schedule was developed.

Partially SupportedLymphokine-activated killer (LAK) cells were ineffective against vascularized tumors in mice but could impact small, non-vascularized tumors.